Axsome Therapeutics: 15min chart triggers Bollinger Bands expansion.

Based on Axsome Therapeutics's 15-minute chart, the Bollinger Bands have exhibited an upward and downward expansion at 14:00 on August 11, 2025. This indicates that the market trend is currently being driven by buyers, suggesting a positive direction, while also being driven by sellers, suggesting a negative direction. The simultaneous expansion of both bands suggests that there is significant volatility and uncertainty in the market, making it difficult to predict the direction of the trend with certainty.

Axsome Therapeutics, Inc. (NASDAQ: AXSM) reported robust financial results for the second quarter of 2025, highlighting significant growth in revenue and expanding market access for its key products. The company's total net product revenue reached $150.0 million, representing a 72% year-over-year (YoY) increase and a 24% sequential growth compared to the first quarter of 2025 [1].

AUVELITY, the company's rapid-acting oral NMDA receptor antagonist and sigma-1 receptor agonist for major depressive disorder, saw its net product sales grow to $119.6 million, up 84% YoY and 24% sequentially. SUNOSI, the dopamine and norepinephrine reuptake inhibitor for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea, reported net product revenue of $30.0 million, a 35% YoY increase and 19% sequential growth [1].

The company also launched SYMBRAVO, a novel, oral, rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor and 5-HT1B/1D agonist for acute treatment of migraine with or without aura, on June 10, 2025. SYMBRAVO's net product sales totaled $0.4 million in its first quarter of availability [1].

Axsome expanded its market access for AUVELITY by 28 million new covered lives in the commercial channel and signed a first group purchasing organization (GPO) contract for SYMBRAVO. Additionally, the company is on track to submit new drug applications for AXS-05 in Alzheimer’s disease agitation in the third quarter and for AXS-12 in narcolepsy in the fourth quarter of 2025 [1].

The company's research and development (R&D) expenses for the second quarter of 2025 were $49.5 million, while selling, general, and administrative (SG&A) expenses were $130.3 million. Total cost of revenue was $13.4 million, resulting in a net loss of $48.0 million for the quarter [1].

Axsome's cash and cash equivalents totaled $303.0 million at June 30, 2025, and the company believes its current cash is sufficient to fund anticipated operations into cash flow positivity [1].

References:

[1] https://www.biospace.com/press-releases/axsome-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-update